NCT01511393
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
Enrolling by Invitation
Not specifiedAges 18+ObservationalNovo Nordisk A/S
~6,750 participants
Updated 2023-06-13 on ClinicalTrials.gov
What's tested:No treatment given
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.
Measured over Up to 15 years
Conditions
Where it's being run
1 sites across 1 statesWest Virginia1
Study leadership
- Annette Stemhagen, DrPH, FISPE · STUDY_DIRECTOR · United BioSource, LLC
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
A record of medullary thyroid carcinoma (MTC) identified from state/regional population-based cancer registries
At least 18 years or older.
What this trial measures
- Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.Up to 15 years